Triamcinolone or Bevacizumab for Central Retinal Vein Occlusion With Poor Vision

This study has been completed.
Sponsor:
Information provided by:
Hallym University Medical Center
ClinicalTrials.gov Identifier:
NCT01053858
First received: January 14, 2010
Last updated: January 20, 2010
Last verified: January 2010

January 14, 2010
January 20, 2010
January 2008
January 2009   (final data collection date for primary outcome measure)
best corrected visual acuity [ Time Frame: baseline, 1 month, 2 months, 3 months, 6 months, 12 months ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT01053858 on ClinicalTrials.gov Archive Site
central macular thickness by optical coherence tomography [ Time Frame: baseline, 1 month, 2 months, 3 months, 6 months 12months ] [ Designated as safety issue: Yes ]
Same as current
Not Provided
Not Provided
 
Triamcinolone or Bevacizumab for Central Retinal Vein Occlusion With Poor Vision
Not Provided

To evaluate the effect of intravitreal bevacizumab with intravitreal triamcinolone for the treatment of central retinal vein occlusion (CRVO) presenting poor visual acuity.

Not Provided
Interventional
Not Provided
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Central Retinal Vein Occlusion With 20/200 or Worse Visual Acuity
Procedure: intravitreal injection
intravitreal bevacizumab( 1.25 mg) or triamcinolone( 4mg) injection
  • Active Comparator: bevacizumab
    intravitreal bevacizumab or triamcinolone determined by single physician
    Intervention: Procedure: intravitreal injection
  • Active Comparator: triamcinolone
    Intervention: Procedure: intravitreal injection
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
38
January 2010
January 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • central macular thickness of more than 250 μm and baseline visual acuity of 20/200 or worse than 20/200 in patient with central retinal vein occlusion

Exclusion Criteria:

  • previous treatment such as intravitreal injection, subtenon injection, or laser photocoagulation since the time of onset
  • Patients with a history of glaucoma, neovascular glaucoma, diabetic retinopathy, and macular disorders
  • neovascularization on the disc or elsewhere or rubeosis
Both
20 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Korea, Republic of
 
NCT01053858
2009_10_12
Yes
Not Provided
Hallym University Medical Center
Not Provided
Not Provided
Hallym University Medical Center
January 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP